While research has lead to the development of effective therapies for some of these disorders, such as the successful application of gene augmentation therapy to treat the severe, early onset form of inherited retinal degeneration (IRD) Leber congenital amaurosis (LCA) caused by mutations in the RPE65 (ENSG00000116745) gene[7-9], therapies for many types of retinal disease remain to be developed. Here, RPE65 is linked to Leber congenital amaurosis.